B2B API Manufacturing Business ModelLasa's core B2B API manufacturing model supplies essential inputs to finished-dosage makers, creating stable, contract-driven demand. The company can leverage product mix (specialty vs commodity APIs) to pursue higher-value sales and steady industrial throughput over time.

Manageable Leverage And Equity FundingThe balance sheet shows moderate debt and a relatively strong equity ratio, providing financial flexibility. Manageable leverage reduces immediate solvency pressure and supports capability to fund restructuring or working-capital needs while pursuing operational improvements.

Product Diversification Across TherapeuticsSupplying APIs and intermediates across multiple therapeutic areas spreads demand risk and reduces concentration on any single indication. That product breadth supports steadier long-term volumes and provides optionality to shift focus toward higher-margin segments.

Bears Say

Sustained Revenue DeclineA multi-year revenue contraction erodes scale economics and weakens pricing leverage. Persistent top-line decline makes it harder to cover fixed manufacturing costs, invest in capacity or certifications, and restore margins without a durable recovery in volumes or higher-value product wins.

Negative Operating And Free Cash FlowNegative operating and free cash flow constrain working capital, capital expenditure and debt servicing. Ongoing cash burn increases the need for external financing or asset sales, which can dilute equity holders or force operational retrenchment absent a sustained turnaround.

Persistent Losses And Negative ROENegative ROE and ongoing losses indicate the company is not converting equity into profit, undermining reinvestment and capital attraction. Over time this weak profitability can impair hiring, R&D or qualification investments needed to regain competitive positioning.

Lasa Supergenerics Ltd. News

Lasa Supergenerics Reinforces Compliance with SDD Certification

Lasa Supergenerics Ltd. ( ($IN:LASA) ) has issued an update. Lasa Supergenerics Ltd. has issued a compliance certificate...

4M ago

LASA

Lasa Supergenerics Announces Key Decisions from Board Meeting

Lasa Supergenerics Ltd. ( ($IN:LASA) ) has issued an announcement. Lasa Supergenerics Ltd. held a board meeting on...

6M ago

LASA

LASA FAQ

What was Lasa Supergenerics Ltd.’s price range in the past 12 months?

Lasa Supergenerics Ltd. lowest stock price was ₹7.59 and its highest was ₹24.44 in the past 12 months.

What is Lasa Supergenerics Ltd.’s market cap?

Lasa Supergenerics Ltd.’s market cap is ₹413.84M.

When is Lasa Supergenerics Ltd.’s upcoming earnings report date?

Lasa Supergenerics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 97 days.

How were Lasa Supergenerics Ltd.’s earnings last quarter?

Lasa Supergenerics Ltd. released its earnings results on Feb 13, 2026. The company reported -₹0.51 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.51.

Is Lasa Supergenerics Ltd. overvalued?

According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lasa Supergenerics Ltd. pay dividends?

Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here

What is Lasa Supergenerics Ltd.’s EPS estimate?

Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lasa Supergenerics Ltd. have?

Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.

What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?

Lasa Supergenerics Ltd. reported an EPS of -₹0.51 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.032%.

Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?

Currently, no hedge funds are holding shares in IN:LASA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lasa Supergenerics Ltd.

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.